Question to the Department of Health and Social Care:

To ask His Majesty's Government what data they are gathering on countries currently implementing immunisation programmes for infant respiratory syncytial virus regarding (1) acceptance and uptake, and (2) hospitalisations.

The UK Health Security Agency continues to monitor international reporting. In the United States, as of 31 January 2024, maternal immunisation was 17.9%. By February 2024, 43% of infants under eight months old had received a dose of nirsevimab.

In Galicia, Spain, 92.9% of 5,357 infants born between 25 September 2023 and 4 February 2024 had nirsevimab, plus 79.7% of 5,823 in a catch-up programme. The peak of hospitalisation rate in infants under six months old was 102 per 100,000, for season 2023 to 2024 during the week starting 27 November 2023 compared to a median of 776 for seasons 2017 to 2018, 2018 to 2019 and 2019 to 2020, peaking during the first week of January 2024.

In Luxembourg, 84% of 1,524 infants born in hospital between early October and mid-December 2023 received nirsevimab. Luxembourg observed a decrease in hospitalisation in infants under six months old of 69% between the 2022 to 2023 and 2023 to 2024 respiratory syncytial virus seasons.